Dren Bio has closed an oversubscribed $350 million private financing round to advance its lead antibody candidate toward ...
Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.
Recent court rulings and USPTO guidance reshape how biotech startups should approach patent strategy for drugs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results